By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – PGXL Labs today announced a partnership for the use of AutoGenomics' Infiniti Analyzer for several personal medicine applications.

PGXL plans to use the Infiniti Warfarin assay and the CYP450 assay, both of which have been cleared by the US Food and Drug Administration, as well as the Infiniti KRAS-BRAF test, it said.

AutoGenomics' Infiniti Analyzer is a microarray-based molecular diagnostics platform for measuring multiple signals from clinical samples.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.